Trial Profile
Interventional, Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of Itraconazole (Inhibitor of CYP3A4/5) on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Idalopirdine (Primary) ; Itraconazole
- Indications Alzheimer's disease; Cognition disorders
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 18 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Apr 2014 New trial record